Averix Bio

Averix Bio is a U.S.-based cannabinoid research and extraction company producing 21 CFR Part 210 and Part 211 and ICH Q7-compliant cGMP API Phytocannabinoid CBD ingredients. The company offers a full array of the highest-quality cannabinoid ingredients for use in the pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Averix Bio ensures consistent quality from seed to shelf, forming the cornerstone of a corporate foundation built on traceability, transparency, and trust. Led by a world-class team with decades of cGMP and pharmaceutical experience, Averix Bio is on a mission to bring healthier cannabinoid-based medical solutions to patients around the world. As a science-first company dedicated to advancing the therapeutic benefits of cannabinoids, our goal is to provide our clients with safe, reliable and efficacious cannabinoid ingredients they can use to expand their business success. We’re committed to building better health outcomes and promoting industry best practices with integrity and accountability.

Website

http://www.averixbio.com

External link for Averix Bio

Industry

Pharmaceutical Manufacturing

Company size

11-50 employees

Headquarters

Wilson, North Carolina

Type

Privately Held

Founded

2018

Specialties

API CBD Isolate, 21 CFR Part 210 Part 211, Cannabinoid Manufacture, Cannabinoid Ingredients, and ICH Q7